Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence November 16, 2022
Onivyde® Regimen Demonstrated Statistically Significant Improvement In Overall Survival In Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma November 16, 2022
COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients November 16, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer November 2, 2022
Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer based on Ph 3 HIMALAYA trial November 2, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 26, 2022
First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients October 26, 2022
Development of CYAD-101, Allogeneic TIM-based, NKG2D CAR T Candidate for Metastatic Colorectal Cancer (mCRC), to be discontinued October 19, 2022
First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Ph 1/2/3 Clinical Study for Natrunix™ Therapy for Colorectal Cancer October 19, 2022
First Patient Enrolled in Part C of Ph 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer October 19, 2022
Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option Announced October 19, 2022
Part 3 of the CORIST Ph 2 trial of SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC) initiated October 12, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
TUKYSA® (tucatinib) + Trastuzumab combo Granted Priority Review by FDA for Previously Treated HER2+ve Metastatic CRC September 28, 2022
Lumakras® (Sotorasib) + Vectibix® (Panitumumab) Shows Confirmed 30% ORR In Patients With KRAS G12C-Mutated mCRC September 13, 2022
Imfinzi + chemo further improved OS benefit in advanced biliary tract cancer in the TOPAZ-1 Ph 3 trial, reducing the risk of death by 24% in additional follow-up September 13, 2022
Adagrasib +/- cetuximab demonstrates promising clinical efficacy and favorable tolerability in heavily pretreated CRC patients with KRASG12C mutation September 13, 2022
Camrelizumab + Rivoceranib (Apatinib) Significantly Prolonged OS & PFS vs Sorafenib in Patients with uHCC in a Multinational Ph 3 Trial September 13, 2022
Results From Ph 3 LEAP-002 Trial of KEYTRUDA® + LENVIMA® Versus LENVIMA Monotherapy in Patients With uHCC presented September 13, 2022
Tislelizumab demonstrated efficacy and tolerability in 1L advanced liver cancer in Ph 3 RATIONALE 301 trial September 13, 2022
Trifluridine/tipiracil + bevacizumab showed a statistically significant OS improvement vs trifluridine/tipiracil alone in Ph 3 trial in mCRC patients September 13, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer September 13, 2022
